ADIL

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Adial is a clinical-stage biopharmaceutical company developing AD04, a therapeutic agent for alcohol use disorder (AUD). The company operates as a single segment focused on drug development for addiction and related disorders. As of the filing date, the company has no approved products and has not generated significant revenue.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt. Current liabilities consist primarily of accounts payable ($573,567) and accrued expenses ($936,504). The company raised approximately $315,000 in net proceeds from the sale of common stock via an At-The-Market (ATM) offering during the quarter.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by approximately $266,000 (12%) to $2.0 million.
  • Research & Development (R&D): Decreased by $314,000 (42%) to $432,530, primarily due to reduced CMC costs and no new data analytics activity.
  • General & Administrative (G&A): Increased by $49,000 (3%) to $1.57 million, driven by higher business development costs.
• Other Income/Expense: Total other income/expense shifted from a net gain of $38,492 in Q1 2025 to a net loss of $20,911 in Q1 2026. This was largely due to the absence of a $150,000 milestone gain recognized in the prior year and a $67,970 loss from an equity method investment (Adovate LLC).
• Capital Structure: The company effected a 1-for-25 reverse stock split on February 5, 2026. All share data in the filing has been retrospectively adjusted. Outstanding shares increased from 1,111,010 to 1,509,200 during the quarter due to ATM sales and warrant exercises.

Outlook, Risks, and Management Commentary

Going Concern Uncertainty

Management and the independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. Cash on hand ($4.6 million) is not expected to be sufficient to fund operations for the next twelve months. The company anticipates funding needs into the second half of 2026 but will require additional capital to sustain operations and complete the development of AD04.

Strategic Developments

• Collaboration Framework: On March 3, 2026, Adial entered into a non-binding collaboration framework with Molteni Farmaceutici for the potential exclusive commercialization of AD04 in Europe. A definitive agreement is expected to include upfront payments, milestones, and royalties, with a potential aggregate value estimated near $60 million. No assurance exists that a definitive agreement will be executed.
• Clinical Strategy: The company plans to conduct one Phase 3 trial with an adaptive enrichment design, followed by a confirmatory Phase 3 trial and an open-label extension study. The company is evaluating regulatory feedback that may allow approval based on one adequate trial plus confirmatory evidence.
• Financing: The company is actively pursuing additional equity or debt financing, including private placements, public offerings, and strategic alternatives (mergers/acquisitions). It maintains an ATM agreement with $4.98 million remaining capacity and a Standby Equity Purchase Agreement (SEPA) with Alumni Capital with $4.9 million remaining.

Risks

• Failure to secure additional funding could force the company to delay or eliminate R&D programs.
• Significant dilution to existing shareholders is expected if additional equity is issued.
• Regulatory approval for AD04 is uncertain and may not occur until 2028 or later.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash exhaustion and the status of ongoing fundraising efforts, given the "substantial doubt" going concern warning.
• European Partnership: Monitor the execution of the definitive agreement with Molteni Farmaceutici and the terms of any upfront payments or milestones.
• ATM Utilization: Track the volume of shares sold under the ATM facility and the impact on share dilution, noting the subsequent sales of ~500,000 shares in April-May 2026.
• Clinical Trial Progress: Confirm the initiation of the planned Phase 3 trial and any updates on the adaptive trial design or regulatory feedback from the FDA.
• Equity Method Investment: Review the financial health of Adovate LLC, as Adial's losses are partially driven by its share of Adovate's operating losses.